Literature DB >> 15485620

Screening and early detection of skin cancer.

Kenneth G Linden1.   

Abstract

Skin cancer is the most common type of cancer in the United States. US incidence of malignant melanoma is increasing faster than any other type of cancer. To minimize increasing morbidity and mortality rates, it is imperative that appropriate screening and early detection of skin cancer become more widespread. All physicians who see patients clinically have the potential for detecting skin cancers. The scope of skin cancer as a health-care problem is discussed. Evidence for the effectiveness and necessity of skin cancer screening and early detection is presented. Costs of screening and detection are discussed in relation to impact on treatment costs and overall costs of skin cancer burden. Current methods and recommendations for skin cancer screening and detection are reviewed, especially with regard to individuals and populations that may require more specialized or intensive screening and follow-up. Newer approaches involving instrument-assisted screening and detection of skin cancer are under intense development, and these exciting emerging technologies are reviewed.

Entities:  

Mesh:

Year:  2004        PMID: 15485620     DOI: 10.1007/s11912-004-0082-6

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  65 in total

1.  Detection and treatment of nonmelanoma skin cancer prevent disfigurement and death.

Authors: 
Journal:  Cutis       Date:  1999-06

Review 2.  Melanoma. Screening and education.

Authors:  M S Ernstoff
Journal:  Clin Plast Surg       Date:  2000-07       Impact factor: 2.017

3.  Audit of a melanoma screening day in the U.K.: clinical results, participant satisfaction and perceived value.

Authors:  S A Holme; S Varma; M M Chowdhury; D L Roberts
Journal:  Br J Dermatol       Date:  2001-11       Impact factor: 9.302

Review 4.  Early detection and treatment of melanoma: update 2000.

Authors:  J K Robinson
Journal:  Dermatol Nurs       Date:  2000-12

Review 5.  NIH Consensus conference. Diagnosis and treatment of early melanoma.

Authors: 
Journal:  JAMA       Date:  1992-09-09       Impact factor: 56.272

6.  Point-counterpoint. Mass population skin cancer screening can be worthwhile--(if it's done right)

Authors:  M A Weinstock
Journal:  J Cutan Med Surg       Date:  1998-01       Impact factor: 2.092

7.  Point-counterpoint. Mass population skin cancer screening is not worthwhile.

Authors:  R H Rampen
Journal:  J Cutan Med Surg       Date:  1998-01       Impact factor: 2.092

8.  Nurses screening for skin cancer: an observation study.

Authors:  P Katris; R J Donovan; B N Gray
Journal:  Aust N Z J Public Health       Date:  1998       Impact factor: 2.939

Review 9.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

10.  Use of an early-detection strategy to improve disease control in melanoma patients.

Authors:  M D Pacifico; R Grover; R Sanders
Journal:  Br J Plast Surg       Date:  2004-03
View more
  3 in total

1.  Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma.

Authors:  Janine G Einspahr; Valerie Calvert; David S Alberts; Clara Curiel-Lewandrowski; James Warneke; Robert Krouse; Steven P Stratton; Lance Liotta; Caterina Longo; Giovanni Pellacani; Giovanni Pellicani; Anil Prasad; Paul Sagerman; Yira Bermudez; Jianghong Deng; G Timothy Bowden; Emanuel F Petricoin
Journal:  Cancer Prev Res (Phila)       Date:  2012-03

2.  Malignant Skin Tumor Misdiagnosed as a Benign Skin Lesion.

Authors:  So-Min Hwang; Hao-Ching Pan; Min-Kyu Hwang; Min-Wook Kim; Jong-Seo Lee
Journal:  Arch Craniofac Surg       Date:  2016-06-21

3.  Vibration analysis of healthy skin: toward a noninvasive skin diagnosis methodology.

Authors:  Rakshita Panchal; Luke Horton; Peyman Poozesh; Javad Baqersad; Mohammadreza Nasiriavanaki
Journal:  J Biomed Opt       Date:  2019-01       Impact factor: 3.170

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.